Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › CA › Marina Del Rey › NPI 1942269725
Hospital

Cedars-Sinai Marina Hospital

Cedars-Sinai Marina Hospital was paid $5.50M by Medicaid between Jan 2018 and Dec 2024, across 118 billing codes. Its largest line is 0450, Emergency room services — 33% of everything it billed.

33Billing provider infoCEDARS-SINAI MARINA HOSPITAL
MARINA DEL REY, CA 90292
33aNPI1942269725assigned 03/21/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.50M
24GClaims287,619
24DCodes billed118
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in California

Rank by total paid#218 of 410
Median peer was paid$6.90M
This provider vs. median0.8×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$50K$100K$150K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201839,047$606K
201936,424$847K
202033,733$640K
202139,691$764K
202245,870$892K
202351,418$940K
2024incomplete41,436$814K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
0450 Emergency room services 33% 51,175 46,790 $1.82M
Z7502 5.1% 7,379 7,257 $279K
70450 Computed tomography, head or brain; without contrast material 4.8% 2,839 2,720 $264K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance 4.6% 7,271 6,769 $252K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 3.7% 11,173 10,316 $206K
99281 Emergency department visit for the evaluation and management, self-limited or minor 3.3% 4,909 4,311 $181K
80053 Comprehensive metabolic panel 3.0% 21,951 20,479 $164K
96375 Therapeutic injection; each additional sequential IV push 2.8% 6,435 5,703 $156K
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 2.7% 2,281 2,127 $147K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc 2.5% 3,662 3,573 $136K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 2.5% 25,097 23,283 $135K
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 2.4% 3,053 2,883 $130K
106 more codes
74176 Computed tomography, abdomen and pelvis; without contrast material 2.0% 1,228 $112K
74177 Computed tomography, abdomen and pelvis; with contrast material 1.9% 665 $106K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 1.9% 2,907 $104K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 1.8% 4,614 $97K
99285 Emergency room visit (most serious) 1.7% 352 $96K
71045 Radiologic examination, chest; single view 1.7% 10,450 $95K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 1.7% 2,499 $93K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular 1.3% 4,690 $74K
C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 1.3% 5,250 $71K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1.2% 1,998 $67K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1.2% 2,190 $64K
96361 Intravenous infusion, hydration; each additional hour <1% 3,065 $42K
84484 <1% 5,312 $34K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 1,800 $33K
0250 <1% 5,642 $33K
99199 Unlisted special service, procedure or report <1% 1,415 $31K
83690 <1% 6,952 $30K
83880 <1% 2,488 $30K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 5,538 $24K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 4,614 $24K
J3490 Unclassified drugs <1% 4,605 $20K
96376 <1% 1,361 $20K
81025 <1% 5,608 $20K
0760 <1% 834 $20K
83605 <1% 2,628 $19K
72125 Computed tomography, cervical spine; without contrast material <1% 176 $19K
80048 Basic metabolic panel (calcium, ionized) <1% 3,486 $16K
J2270 Injection, morphine sulfate, up to 10 mg <1% 2,564 $15K
81001 <1% 5,975 $13K
87040 <1% 1,450 $13K
J7030 Infusion, normal saline solution , 1000 cc <1% 3,036 $12K
0270 <1% 1,671 $12K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 1,738 $11K
87088 <1% 2,796 $10K
99282 Emergency department visit for the evaluation and management, low to moderate severity <1% 574 $9K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 702 $9K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 599 $8K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 582 $8K
99221 <1% 446 $7K
85610 <1% 3,061 $7K
85027 <1% 1,972 $7K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 437 $7K
81002 <1% 3,689 $6K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 193 $6K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 1,278 $6K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 156 $5K
71275 Computed tomographic angiography, chest, with contrast material <1% 61 $5K
85379 <1% 808 $4K
73562 <1% 308 $4K
85730 <1% 1,254 $4K
87077 <1% 1,036 $4K
73610 <1% 183 $4K
73630 <1% 181 $3K
J2060 Injection, lorazepam, 2 mg <1% 943 $3K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 66 $3K
90715 <1% 130 $3K
73130 <1% 198 $2K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 600 $2K
93971 <1% 65 $2K
81003 <1% 1,936 $2K
G0378 Hospital observation service, per hour <1% 19 $2K
87186 <1% 369 $2K
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 154 $1K
82962 <1% 315 $1K
71046 Radiologic examination, chest; 2 views <1% 59 $1K
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 345 $1K
0324 <1% 77 $1K
0301 <1% 30 $1K
83735 <1% 382 $980.06
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 60 $977.68
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 197 $973.85
84702 <1% 132 $895.97
S0119 Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) <1% 217 $879.03
84703 <1% 150 $827.46
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 153 $816.55
85007 <1% 414 $767.93
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 27 $763.41
80329 <1% 84 $728.74
80320 <1% 262 $577.55
Z7610 <1% 34 $573.75
86901 <1% 244 $569.55
86900 <1% 253 $535.90
87086 Culture, bacterial; quantitative colony count, urine <1% 184 $462.13
73110 <1% 27 $422.45
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 98 $401.68
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 25 $339.09
J7613 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg <1% 66 $310.75
0637 <1% 377 $304.20
87400 <1% 137 $294.01
J7620 Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme <1% 238 $258.91
96368 <1% 14 $257.80
73030 <1% 27 $192.53
0272 <1% 854 $116.12
A4649 Surgical supply; miscellaneous <1% 297 $109.26
0206 <1% 12 $77.54
J1630 Injection, haloperidol, up to 5 mg <1% 30 $77.27
96367 <1% 12 $70.03
87070 <1% 12 $69.36
0271 <1% 836 $57.62
87081 <1% 13 $52.17
C9113 Injection, pantoprazole sodium, per vial <1% 31 $19.42
86850 <1% 12 $18.09
J2471 Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg <1% 19 $16.55
0636 <1% 17 $2.26
0305 0% 12 $0.00
0306 0% 12 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMAQUEIRA, LISA (VP, FINANCE AND CRO)